Glucagon-like peptide-1 receptor agonists such as Ozempic have surged in popularity over the past year. But what does this increased popularity mean for the ASC industry?
Glucagon-like peptide-1 receptor agonists such as Ozempic have surged in popularity over the past year. But what does this increased popularity mean for the ASC industry?